scispace - formally typeset
T

T Lockett

Researcher at University of Oxford

Publications -  7
Citations -  1637

T Lockett is an academic researcher from University of Oxford. The author has contributed to research in topics: Cytotoxic T cell & CD8. The author has an hindex of 5, co-authored 7 publications receiving 899 citations.

Papers
More filters
Journal ArticleDOI

Broad and strong memory CD4 + and CD8 + T cells induced by SARS-CoV-2 in UK convalescent individuals following COVID-19.

TL;DR: The identification of T cell responses associated with milder disease will support an understanding of protective immunity and highlights the potential of including non-spike proteins within future COVID-19 vaccine design.
Journal ArticleDOI

Performance characteristics of five immunoassays for SARS-CoV-2: a head-to-head benchmark comparison

Mark A. Ainsworth, +130 more
TL;DR: Four commercial, widely available assays and a scalable 384-well ELISA can be used for SARS-CoV-2 serological testing to achieve sensitivity and specificity of at least 98%.
Journal ArticleDOI

COVID-19: Rapid antigen detection for SARS-CoV-2 by lateral flow assay: A national systematic evaluation of sensitivity and specificity for mass-testing.

T Peto, +270 more
- 01 Jun 2021 - 
TL;DR: In this article, the authors evaluated the performance of Lateral flow device (LFD) immunoassays for SARS-CoV-2 infection and found that they have promising performance characteristics for mass population testing and can be used to identify infectious positive individuals.
Posted ContentDOI

Broad and strong memory CD4+and CD8+T cells induced by SARS-CoV-2 in UK convalescent COVID-19 patients

TL;DR: The identification of T cell specificity and functionality associated with milder disease, highlights the potential importance of including non-spike proteins within future COVID-19 vaccine design.
Journal ArticleDOI

A haemagglutination test for rapid detection of antibodies to SARS-CoV-2.

TL;DR: A quantitative Haemagglutination test (HAT) was proposed in this article for the detection of antibodies to the receptor binding domain of the SARS-CoV-2 spike protein.